- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01075997
The Impact of a Video Cell Phone Reminder System on Glycemic Control in Patients With Diabetes Mellitus
24 février 2010 mis à jour par: Walter Reed Army Medical Center
The purpose of the study is to determine whether having a video cell phone that gives daily reminders over a 6-month period to check blood surgery and take your diabetes medications can improve your diabetes control during that time and if that benefit lasts for up to 1 year.
Aperçu de l'étude
Statut
Inconnue
Les conditions
Intervention / Traitement
Description détaillée
The purpose of this study is to determine if a cell phone video reminder system will improve compliance and glycemic control in patients with diabetes mellitus when compared with standard of care.
We plan to partner with Affinity Network, Inc., a local minority-owned small business, to provide broadband-enabled cell phone service to patients with diabetes mellitus.
Their IntelaCare™ system will host the content and transmit it to the phones on a personalized schedule.
This will be a prospective, randomized, controlled trial comparing patients with diabetes mellitus who receive daily video reminders via cell phone to take their medications and check their blood glucose with patients who are just given a cell phone without daily reminders.
The primary endpoint will be improvement of glycemic control as measured by glycosylated hemoglobin (A1c).
The secondary endpoints will compare mean daily glucose levels, the number of both hypoglycemic and hyperglycemic events, the amount of time spent in target blood glucose, and the perceived level of diabetes-related stress between the two groups.
Patients in both groups will receive a broad-band enabled cell phone and cell phone service for the duration of the study.
Patients will be randomized into a "cell phone" group (group A) and a "cell phone plus reminder" group (group B).
They will be seen by their provider at least quarterly (or more often as clinically appropriate).
Blood glucose readings will be downloaded from patients' glucometers at every provider visit (at least quarterly).
Group B will receive a daily 15-second video from their provider reminding them to take their medication and to test their blood sugar and an educational "tip-of-the day."
These reminders will be personalized and recorded by their provider.
During the second 6 months, the patients will be followed by their provider at least quarterly.
Improvement in glycemic control will be determined by quarterly measurements of A1c and the mean and standard deviation of blood glucose.
In addition, the number of home blood glucose tests performed on a weekly basis will be compared.
Compliance with medication will be determined by pharmacy refill records and pill counts.
Quality-of-life will be measures using 2 validated instruments at 0, 26 and 52 weeks - the Problem Areas in Diabetes (PAID), which is a diabetes-related quality of life questionnaire and the SF-8, which is a general quality of life questionnaire for people with chronic disease.
Type d'étude
Interventionnel
Inscription (Anticipé)
170
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
District of Columbia
-
Washington DC, District of Columbia, États-Unis, 20307
- Walter Reed Army Hospital Center
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 89 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- age 18 or greater
- A1c greater than 8%
- ability to use a cell phone and glucose meter
- ability to understand English
- on oral therapy and/or insulin
Exclusion Criteria:
- under age 18
- non-English speaking
- females who are pregnant, lactating, planning to become pregnant, or without a safe contraceptive method
- A1c less than 8%
- use of glucocorticoids, amphetamines, anabolic, or weight-reducing agents during the course of the study
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: A cell phone tips
This group will receive a cell phone and cell phone service for 1 year.
This group will receive a daily video reminders and tips for the first 6 months of the study.
For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent.
The group will be instructed on how to use the cell phone.
The group will be asked to check blood sugar on a schedule determined by their providers.
The group will have blood sugars downloaded from from the glucometer by their providers at every visit and reviewed.
The group will have the A1c measured.
Also it will have this test repeated about every 3 months.
They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
|
This group will receive a cell phone and cell phone service for 1 year.
This group will receive a daily video reminders and tips for the first 6 months of the study.
For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent.
The group will be instructed on how to use the cell phone.
Autres noms:
|
Comparateur actif: B no cell phone tips
This group will receive a cell phone and cell phone service for 1 year.
For the second 6 months this group will be seen by their providers at least every 3 months.
The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by their provider.
The groups will have blood sugars downloaded from from the glucometer by their provider at every visit and reviewed.
The group will have A1c measured.
Also it will have this test repeated about every 3 months.
They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
|
This group will receive a cell phone and cell phone service for 1 year.
For the second 6 months this group will be seen by their providers at least every 3 months.
The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider.
The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
The primary endpoint will be improvement of glycemic control as measured by glycosylated hemoglobin (A1c).
Délai: week 0, week 12, week 26, week 38, week 52
|
week 0, week 12, week 26, week 38, week 52
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
To compare mean blood glucose levels,the number of hypo- and hyperglycemic events,the duration of time spent in target blood glucose range,the perceived level of diabetes-related stress and the perceived effect of diabetes on quality of life.
Délai: week 0, week 12, week 26, week 38, week 52
|
week 0, week 12, week 26, week 38, week 52
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Amanda Bell, MD, WRAMC
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 novembre 2007
Achèvement primaire (Anticipé)
1 juillet 2010
Achèvement de l'étude (Anticipé)
1 octobre 2010
Dates d'inscription aux études
Première soumission
24 février 2010
Première soumission répondant aux critères de contrôle qualité
24 février 2010
Première publication (Estimation)
25 février 2010
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
25 février 2010
Dernière mise à jour soumise répondant aux critères de contrôle qualité
24 février 2010
Dernière vérification
1 juin 2009
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- WU#07-13025
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .